Калкулатор за MOTS-c

What Is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded not by the nuclear genome but by mitochondrial DNA — specifically within the 12S ribosomal RNA gene. It was first identified in 2015 by researchers at the University of Southern California, led by Pinchas Cohen, marking a paradigm shift in our understanding of mitochondria as endocrine-like signaling organelles rather than passive energy factories.

MOTS-c is produced in mitochondria across multiple tissues, released into circulation, and acts as a systemic metabolic hormone. Plasma concentrations decline with age and are lower in individuals with obesity, type 2 diabetes, and metabolic syndrome — positioning MOTS-c as both a biomarker and a therapeutic target for age-related metabolic dysfunction.

The peptide is sometimes described as an "exercise mimetic" because its administration recapitulates key metabolic adaptations induced by physical exercise: improved insulin sensitivity, enhanced fatty acid oxidation, increased skeletal muscle glucose uptake, and reduced adiposity — without requiring the exercise itself. This has generated significant research interest in applications ranging from metabolic disease to healthy aging and longevity protocols.

Mechanism of Action

MOTS-c operates through several interconnected metabolic pathways:

• AMPK activation: MOTS-c activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. AMPK activation increases glucose uptake in skeletal muscle, enhances fatty acid oxidation, inhibits lipogenesis, and upregulates mitochondrial biogenesis — effects closely mirroring those of exercise and caloric restriction.
• Folate cycle and AICAR pathway: MOTS-c inhibits the enzyme MTHFR (methylenetetrahydrofolate reductase) within mitochondria, diverting folate metabolism toward AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a natural AMPK activator. This creates an internal metabolic signal that drives energy expenditure programs.
• Insulin sensitization: By activating AMPK and improving mitochondrial efficiency, MOTS-c markedly enhances insulin sensitivity in skeletal muscle and liver. Studies in high-fat diet mouse models show normalization of blood glucose and improved glucose tolerance following MOTS-c administration.
• Anti-inflammatory signaling: MOTS-c translocates to the nucleus under metabolic stress conditions, where it modulates nuclear gene expression including suppression of NF-κB-driven inflammatory pathways. This nuclear signaling role was characterized in research published in Cell Metabolism (2021).
• Mitochondrial function and biogenesis: MOTS-c upregulates PGC-1α (peroxisome proliferator-activated receptor-gamma coactivator 1-alpha), the primary transcriptional regulator of mitochondrial biogenesis, increasing both mitochondrial number and respiratory capacity in skeletal muscle.

Dosage and Dosing Protocol

MOTS-c research is still evolving, and human clinical trials are limited. The dosing parameters below reflect current research protocols and the community consensus among peptide researchers. Use the MOTS-c Calculator to calculate exact injection volumes for your vial concentration.

Typical Dosing Range

• Conservative starting dose: 5 mg per injection, once weekly
• Standard research dose: 5–10 mg per injection, once or twice weekly
• Higher range: 10 mg per injection (experienced researchers, specific metabolic goals)

Protocol Structure

Unlike peptides dosed daily, MOTS-c is typically administered on a weekly schedule:

• Frequency: Once weekly subcutaneous injection is standard. Some researchers use twice-weekly for more aggressive metabolic interventions.
• Injection site: Subcutaneous injection into the abdomen or lateral thigh. Some protocols time the injection pre-exercise to leverage potential synergies with exercise-induced AMPK activation.
• Cycle length: Most protocols run 8–12 weeks followed by a 4-week break. Longer cycles may lead to receptor adaptation, though this has not been formally studied.
• Half-life considerations: With an estimated half-life of approximately 12 hours, MOTS-c is cleared relatively quickly. Weekly dosing maintains intermittent supraphysiologic peaks rather than sustained elevated levels, which may better mimic natural pulsatile secretion patterns.

A standard 5 mg vial reconstituted with 2 mL bacteriostatic water yields a concentration of 2.5 mg/mL. A 5 mg dose therefore requires 2.0 mL using a 1.0 mL syringe (two full draws or a single draw from a 2 mL syringe). View MOTS-c at BergdorfBio for purchasing options.

Reconstitution

MOTS-c is supplied as a lyophilized (freeze-dried) powder, typically in 5 mg or 10 mg vials. It must be reconstituted with bacteriostatic water (BAC water) before use.

1. Allow the vial to reach room temperature before opening (approximately 15–20 minutes from the refrigerator or freezer).
2. Clean the rubber stopper of both the peptide vial and the BAC water vial with a 70% isopropyl alcohol swab. Allow to dry for 30 seconds.
3. Draw 2 mL of BAC water into a sterile syringe. For a 5 mg vial, this yields a concentration of 2.5 mg/mL. For a 10 mg vial, use 2 mL for a concentration of 5 mg/mL.
4. Insert the needle at an angle against the inner glass wall of the peptide vial. Slowly depress the plunger, letting the water trickle down the wall — do not jet it directly onto the lyophilized cake, as this can damage the peptide structure.
5. Gently swirl the vial using a slow rotating motion until the powder is fully dissolved. The solution should be clear and colorless. Do not shake or vortex.
6. Label the vial with the reconstitution date and concentration (e.g., "2.5 mg/mL, reconstituted [date]").

Use the MOTS-c Peptide Calculator to determine the precise draw volume for any dose and concentration combination.

Storage and Shelf Life

• Lyophilized powder (unreconstituted): Store at −20°C (freezer) for long-term stability, up to 24 months. Short-term storage at 4°C (refrigerator) is acceptable for up to 3 months. Keep away from light and moisture. Do not store in a frost-free freezer, which undergoes temperature cycling.
• Reconstituted solution: Store at 2–8°C (refrigerator). Use within 28–30 days of reconstitution. Keep upright and protected from light. Do not freeze the reconstituted solution — freeze-thaw cycles cause peptide aggregation and loss of biological activity.
• Transport: Use an insulated cooler bag with an ice pack. Avoid exposure to temperatures above 25°C for more than brief periods.
• Inspection: Discard the reconstituted solution if it becomes cloudy, discolored, or shows particulate matter — any of these indicate degradation or microbial contamination.

Side Effects and Safety

Human safety data on MOTS-c remains limited, and the peptide is classified strictly as a research compound. Based on available animal studies and self-reported human research experience:

Commonly Reported Observations

• Injection site reactions: Mild redness, slight swelling, or transient discomfort at the subcutaneous injection site — typically resolving within 1–2 hours.
• Transient fatigue: Some researchers report mild fatigue or drowsiness in the hours following injection, particularly at the start of a protocol. This may reflect metabolic adaptation driven by AMPK activation.
• Mild hypoglycemic tendency: MOTS-c's insulin-sensitizing effects can lower blood glucose. Individuals with pre-existing hypoglycemia susceptibility or those taking glucose-lowering medications should exercise caution and monitor blood sugar.

Precautions

• MOTS-c has not been tested in pregnant or breastfeeding individuals. Avoid use in these populations.
• Individuals on metformin, insulin, or other glucose-modulating agents should be aware of potential additive hypoglycemic effects.
• No studies have evaluated MOTS-c interactions with pharmaceutical drugs. Use with caution alongside any medication affecting glucose metabolism or mitochondrial function.

No serious adverse events have been attributed to MOTS-c in published animal research at doses comparable to human research protocols. Long-term human safety data is not yet available.

Combinations and Stacks

MOTS-c + SS-31 (Mitochondrial Stack)

The combination of MOTS-c and SS-31 (Elamipretide) represents a powerful dual-mechanism approach to mitochondrial optimization. While MOTS-c activates AMPK and drives metabolic reprogramming at the systems level, SS-31 directly targets cardiolipin in the inner mitochondrial membrane, restoring electron transport chain efficiency and reducing reactive oxygen species (ROS). Together, they address both the signaling deficits and the structural damage that characterize mitochondrial aging.

• MOTS-c: 5–10 mg subcutaneous, once weekly
• SS-31: 0.5 mg subcutaneous, daily
• Cycle: 8–12 weeks with 4-week washout

MOTS-c + AOD-9604

For body composition goals, stacking MOTS-c with AOD-9604 — the lipolytic C-terminal fragment of human growth hormone — combines AMPK-driven metabolic enhancement with direct fat cell signaling. AOD-9604 stimulates lipolysis in adipocytes via beta-3 adrenoreceptors while inhibiting de novo lipogenesis. Combined with MOTS-c's improvement in fatty acid oxidation and insulin sensitivity, this stack addresses fat metabolism through complementary pathways.

MOTS-c Alone for Metabolic Health

Many researchers begin with MOTS-c as a standalone compound, particularly for insulin resistance, weight management, or longevity goals. Its broad metabolic effects and once-weekly dosing make it one of the more practical peptides for long-term research protocols.

Frequently Asked Questions

What makes MOTS-c different from other metabolic peptides?

MOTS-c is unique in being encoded by mitochondrial DNA rather than nuclear DNA — it is the first mitochondria-derived peptide shown to act as a systemic hormone. This gives it a mechanistic profile distinct from peptides like AOD-9604 or CJC-1295: rather than acting on a single receptor, it reprograms cellular metabolism at the level of energy sensing (AMPK) and gene expression.

How soon do metabolic effects become noticeable?

In animal models, significant improvements in insulin sensitivity and glucose tolerance appear within 2–4 weeks of weekly administration. Human researchers often report subjective improvements in energy levels and exercise recovery within 3–6 weeks. Body composition changes, if they occur, typically require 8–12 weeks to assess.

Does MOTS-c require post-cycle therapy?

No. MOTS-c does not interact with the hypothalamic-pituitary-gonadal (HPG) axis and does not suppress endogenous hormone production. No PCT is required after a MOTS-c cycle.

Can MOTS-c be used alongside exercise?

Yes, and this is one of the most scientifically interesting aspects of MOTS-c research. Because MOTS-c activates the same AMPK pathways as exercise, combining the two may produce additive or synergistic effects on metabolic adaptation. Some researchers inject MOTS-c 30–60 minutes before training sessions for this reason.

Is MOTS-c suitable for older individuals targeting longevity?

MOTS-c is one of the most actively researched peptides in the longevity field. Its decline with age, its role in mitochondrial function, and its ability to recapitulate metabolic youth markers make it a compelling subject. Several longevity researchers include it specifically because it targets the mitochondrial aging axis — a pathway implicated in hallmarks of aging including energy decline, insulin resistance, and chronic inflammation.

Can women use MOTS-c?

Yes. MOTS-c's mechanisms are not sex-hormone dependent. Research has been conducted in both male and female animal models with consistent metabolic improvements observed across sexes. Human protocols are used by both men and women without sex-specific dosing adjustments currently indicated.

What syringe size is appropriate for MOTS-c injections?

Given the typical dose volume of 2.0 mL for a 5 mg dose at 2.5 mg/mL concentration, a 1.0 mL insulin syringe is not sufficient for a single draw. A 2.5 mL or 3 mL low-dead- volume syringe with a 29–31 gauge, 0.5-inch needle is recommended. Alternatively, two sequential 1.0 mL draws injected at adjacent subcutaneous sites is a practical approach.

How does MOTS-c compare to Metformin?

Both MOTS-c and metformin activate AMPK, but through distinct mechanisms. Metformin inhibits mitochondrial complex I, which secondarily elevates AMP:ATP ratio and activates AMPK. MOTS-c works via the MTHFR/AICAR pathway to produce a more upstream and physiologically derived AMPK signal. Unlike metformin, MOTS-c does not impair mitochondrial respiration — it enhances it. The two have not been formally studied in combination in humans.

Medical Disclaimer: The information on this page is provided for educational and research purposes only. MOTS-c is not an approved drug or medical treatment. It is sold strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.